SCHEMBL4674702

SCHEMBL4674702

O=C(O)/C(O)=C/C(=O)c1cc[nH]c1Cc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.36
PLA2G2A P14555 1/20 0.36
HNF4A P41235 1/20 0.36
CDC7 O00311 1/20 0.34
CYP2C9 P11712 3/20 0.33
CYP3A4 P08684 2/20 0.33
MPO P05164 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
LMNA P02545 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
ACMSD Q8TDX5 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB2 P47870 1/20 0.32
CALM1 P0DP23 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674707 1.00 PLA2G10 (0.36) PLA2G10PLA2G2AHNF4ACDC7CYP2C9
SCHEMBL4676292 0.87 SRD5A2 (0.37) LMNACA12CA1CA2CA9
SCHEMBL4673838 0.87 CTBP2 (0.34) CYP1A2CYP2C19LMNACA12CA1
SCHEMBL4671742 0.87 ITGB1 (0.35) PLA2G10PLA2G2ACYP3A4
SCHEMBL4671740 0.87 ITGB1 (0.35) PLA2G10PLA2G2ACYP3A4
SCHEMBL4674176 0.87 CDC7 (0.37) CDC7CYP3A4GABRA1GABRB2HDAC6
SCHEMBL4674177 0.87 CDC7 (0.37) CDC7CYP3A4GABRA1GABRB2HDAC6
SCHEMBL4673842 0.87 CTBP2 (0.34) CYP1A2CYP2C19LMNACA12CA1
SCHEMBL4676294 0.87 SRD5A2 (0.37) LMNACA12CA1CA2CA9
SCHEMBL4672352 0.87 HCAR2 (0.41) HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PLA2G10 4884/4885PLA2G2A 4877/4885HNF4A 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.